Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Maro Ohanian, Martha L. Arellano, Moshe Y. Levy, Kristen O'Dwyer, Hani Babiker, Daruka Mahadevan, Hongying Zhang, Nasrin Rastgoo, Yuying Jin, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar

Blood (2021) 138 (Supplement 1): 3411.

https://doi.org/10.1182/blood-2021-150049

Published: 2021

Journal Articles

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Aaron D Goldberg, Maro Ohanian, Paul Koller, Jessica K. Altman, Mohamad Cherry, Benjamin Tomlinson, Namrata Chandhok, Hongying Zhang, Nasrin Rastgoo, Khalid Benbatoul, Yuying Jin, Genia Su, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar

Blood (2021) 138 (Supplement 1): 1272.

https://doi.org/10.1182/blood-2021-149333

Published: 2021

Journal Articles

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies

Blood (2021) 138 (Supplement 1): 1355.

https://doi.org/10.1182/blood-2021-148827

Published: 2021

Journal Articles

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Rafael Bejar, MD PhD, Hongying Zhang, MDPhD, Nasrin Rastgoo, PhD, Khalid Benbatoul, BS, Yuying Jin, PhD, Matthew Thayer, BS., Susan Sheng, PhD, Gregory k Chow, BA, MBA, Victor Montalvo-Lugo, Jotin Marango, MD, Stephen B Howell, MD, William G Rice, PhD

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-141495

Published: 2020

Journal Articles

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-141409

Published: 2020

Journal Articles

A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Stephen B Howell, MD, Hongying Zhang, MD PhD, William G Rice, PhD

Blood (2019) 134 (Supplement_1): 5477.

https://doi.org/10.1182/blood-2019-130784

Published: 2019

Journal Articles

A Phase 1a/b Dose Escalation Study of Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Stephen B Howell, MD, Hongying Zhang, MD PhD, William G Rice, PhD

Blood (2019) 134 (Supplement_1): 5148.

https://doi.org/10.1182/blood-2019-129685

Published: 2019

Journal Articles

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Cheng-Yu Tsai, PhD, Hongying Zhang, MD PhD, William G Rice, PhD, Stephen B Howell, MD

Blood (2019) 134 (Supplement_1): 5755.

https://doi.org/10.1182/blood-2019-123571

Published: 2019

Journal Articles

Mechanisms of Resistance to Apto-253

Cheng-Yu Tsai, PhD, Hongying Zhang, MD PhD, Andrea Local, PhD, William G. Rice, PhD, Stephen B Howell, MD

Blood (2016) 128 (22): 5247.

https://doi.org/10.1182/blood.V128.22.5247.5247

Published: 2016

Journal Articles

Broad Activity of Apto-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level

Stephen E. Kurtz, PhD, Daniel Bottomly, MS, Beth Wilmot, PhD, Shannon K. McWeeney, PhD, William Rice, PhD, Stephen B Howell, MD, Avanish Vellanki, Brian J. Druker, MD, Jeffrey W. Tyner, PhD

Blood (2015) 126 (23): 1358.

https://doi.org/10.1182/blood.V126.23.1358.1358

Published: 2015

Journal Articles

Clinical Pharmacokinetics of Apto-253 Support Its Use As a Novel Agent for the Treatment of Relapsed or Refractory Hematologic Malignancies

William G. Rice, PhD, Jeff Lightfoot, PhD, Hongying Zhang, MD PhD, Tiffany Cheng, MSc, Avanish Vellanki, Robert Peralta, MSc, DVM, Stephen B Howell, MD, Andrea Local, Fannie Chau, Luis Esquivies

Blood (2015) 126 (23): 4934.

https://doi.org/10.1182/blood.V126.23.4934.4934

Published: 2015

Journal Articles

A6 Peptide Is Selectively Cytotoxic For Chronic Lymphocytic Leukemia Cells

Suping Zhang, PhD, Hsien Lai, BS, Grace Liu, Laura Rassenti, PhD, Michael Y. Choi, MD, Stephen B Howell, MD, Malcolm Finlayson, PhD, Thomas J. Kipps, MD, PhD

Blood (2013) 122 (21): 5303.

https://doi.org/10.1182/blood.V122.21.5303.5303

Published: 2013

NARROW

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

A Phase 1a/b Dose Escalation Study of Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Mechanisms of Resistance to Apto-253

Broad Activity of Apto-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level

Clinical Pharmacokinetics of Apto-253 Support Its Use As a Novel Agent for the Treatment of Relapsed or Refractory Hematologic Malignancies

A6 Peptide Is Selectively Cytotoxic For Chronic Lymphocytic Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only